Sugi Predict

Sugi Predict / Compounds / SCHEMBL20883145

SCHEMBL20883145

SCHEMBL20883145

Cn1cc(C(=O)C(=O)NC2CCCC2)c2cc(C(=O)N3CCC(Cc4ccc(F)cc4)CC3)c(Cl)cc21

nearest known ligand 0.56

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 11/20 0.56
▸ MAPK11 Q15759 2/20 0.49
▸ MAPK13 O15264 1/20 0.49
▸ MAPK12 P53778 1/20 0.49
▸ NQO2 P16083 1/20 0.49
▸ MAPKAPK2 P49137 1/20 0.49
▸ ACTR2 P61160 1/20 0.49
▸ RAB9A P51151 1/20 0.46
▸ CCR3 P51677 1/20 0.43
▸ CHRM2 P08172 2/20 0.42
▸ GFER P55789 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5204882 0.97 MAPK14 (0.58) MAPK14MAPK11MAPK13MAPK12NQO2
SCHEMBL5203616 0.89 MAPK14 (0.56) MAPK14MAPK11MAPK13MAPK12NQO2
SCHEMBL20883127 0.89 MAPK14 (0.58) MAPK14MAPK11MAPK13MAPK12NQO2
SCHEMBL5204937 0.88 MAPK14 (0.57) MAPK14MAPK11MAPK13MAPK12NQO2
SCHEMBL5204930 0.88 MAPK14 (0.61) MAPK14MAPK11MAPK13MAPK12NQO2
SCHEMBL20883158 0.87 MAPK14 (0.62) MAPK14MAPK11MAPK13MAPK12NQO2
SCHEMBL5202008 0.87 MAPK14 (0.59) MAPK14MAPK11MAPK13MAPK12NQO2
SCHEMBL5202317 0.87 MAPK14 (0.59) MAPK14MAPK11MAPK13MAPK12NQO2
SCHEMBL5201155 0.87 MAPK14 (0.61) MAPK14MAPK11MAPK13MAPK12NQO2
SCHEMBL5201793 0.86 MAPK14 (0.59) MAPK14MAPK11MAPK13MAPK12NQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11291659-B2 P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD Fulcrum Therapeutics, Inc. (US) 2022-04-05 — — US disclosed
US-20200383963-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD Fulcrum Therapeutics, Inc. 2020-12-10 — — US disclosed
US-10342786-B2 P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD Fulcrum Therapeutics, Inc. (US) 2019-07-09 — — US disclosed
US-20190105311-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD Fulcrum Therapeutics, Inc. 2019-04-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200383963-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD ZFX, TBL1XR1, RHOXF2 MAPK14 193/4885MAPK11 726/4885MAPK13 286/4885
US-20190105311-A1 P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD ZFX, TBL1XR1, TRIM28 MAPK14 196/4885MAPK11 866/4885MAPK13 304/4885
US-10342786-B2 P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD ZFX, TBL1XR1, TRIM28 MAPK14 191/4885MAPK11 857/4885MAPK13 303/4885
US-11291659-B2 P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD ZFX, TBL1XR1, TRIM28 MAPK14 191/4885MAPK11 857/4885MAPK13 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.